Quality of life in ovarian cancer

Cancer Control

Volumn 18, Issue 1, 2011, Pages 52-58

  Grzankowski, Kassondra S ^a   Carney, Michael ^a  

^a UNIVERSITY OF HAWAII   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; PACLITAXEL;

ARTICLE; CANCER CHEMOTHERAPY; FUNCTIONAL DISEASE; HEALTH CARE COST; HUMAN; NEUROTOXICITY; OVARY CANCER; PATIENT ATTITUDE; PATIENT CARE; PATIENT MOBILITY; QUALITY OF LIFE; SEXUALITY; SOCIAL PSYCHOLOGY; SOCIAL STATUS; SYMPTOMATOLOGY; SYSTEMIC THERAPY;

EID: 78651515796     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481101800108     Document Type: Article

References (40)

1. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, ed. Evaluation of Chemotherapeutic Agents. New York, NY: Columbia University Press; 1949:196.
2. Cella D, Wagner L, Cashy J, et al. Should health-related quality of life be measured in cancer symptom management clinical trials? Lessons learned using the functional assessment of cancer therapy. J Natl Cancer Inst Monogr. 2007;(37):53-60.
3. Marcos Del Cano AM. The concept of quality of life: legal aspects. Med Health Care Philos. 2001;4(1):91-95.
4. Cella DF. Measuring quality of life in palliative care. Semin Oncol. 1995;22(2 suppl 3):73-81.
5. Gotay CC, Korn EL, McCabe MS, et al. Quality-of-life assessment in cancer treatment protocols: research issues in protocol development. J Natl Cancer Inst. 1992;84(8):575-579.
6. Johnson JR, Temple R. Food and Drug Administration requirements for approval of new anticancer drugs. Cancer Treat Rep. 1985;69(10):1155-1159.
7. Kübler-Ross E. On Death and Dying. New York, NY: Macmillan; 1969.
8. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
9. American Cancer Society [Web site]. http://www.cancer.org/docroot/ home/index.asp. Accessed October 5, 2010.
10. Eltabbakh GH. Recent advances in the management of women with ovarian cancer. Minerva Ginecol. 2004;56(1):81-89.
11. National Library of Medicine Consensus Conference Reports 1992-1994. Ovarian cancer: screening, treatment, and follow-up. NIH Consensus Statement Online. April 5-7,1994. http://hstat.nlm.nih.gov. Accessed October 5, 2010.
12. Dunton CJ. New options for the treatment of advanced ovarian cancer. Semin Oncol. 1997;24(1 suppl 5):S5-2-S5-11.
13. Mercado C, Zingmond D, Karlan BY, et al. Quality of care in advanced ovarian cancer: the importance of provider specialty. Gynecol Oncol. 2010;117(1):18-22.
14. Lister-Sharp D, McDonagh MS, Khan KS, et al. A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer. Health Technol Assess. 2000;4(17):1-113.
15. Högberg T, Glimelius B, Nygren P, et al. A systematic overview of chemotherapy effects in ovarian cancer. Acta Oncol. 2001;40(2-3):340-360.
16. Kaye SB. Future directions for the management of ovarian cancer. Eur J Cancer. 2001;37(suppl 9):S19-S23.
17. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334(1):1-6.
18. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000;92(9):699-708.
19. Neijt JP, Engelholm SA, Tuxen MK, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol. 2000;18(17):3084-3092.
20. du Bois A, Lück HJ, Meier W, et al. A randomized clinical trial of cisplatin/ paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95(17):1320-1329.
21. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21(17):3194-3200.
22. Lakusta CM, Atkinson MJ, Robinson JW, et al. Quality of life in ovarian cancer patients receiving chemotherapy. Gynecol Oncol. 2001;81(3):490-495.
23. Guastalla JP 3rd, Diéras V. The taxanes: toxicity and quality of life considerations in advanced ovarian cancer. Br J Cancer. 2003;89(suppl 3): S16-S22.
24. Michaud LB, Valero V, Hortobagyi G. Risks and benefits of taxanes in breast and ovarian cancer. Drug Saf. 2000;23(5):401-428.
25. Vasey P, on behalf of the Scottish Gynaecologic Cancer Trials Group. Preliminary Results of the SCOTROC Trial: a Phase III Comparison of Paclitaxel-Carboplatin (PC) and Docetaxel-Carboplatin (DC) as First-Line Chemotherapy for Stage Ic-IV Epithelial Ovarian Cancer (EOC). Proc Am Soc Clin Oncol. 2001;20:804. Abstract.
26. Vasey PA, Atkinson R, Coleman R, et al. Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. Br J Cancer. 2001;84 (2):170-178.
27. Wenzel LB, Huang HQ, Armstrong DK, et al. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(4):437-443.
28. von Gruenigen VE, Huang HQ, Gil KM, et al. A comparison of quality of life domains and clinical factors in ovarian cancer patients: a Gynecologic Oncology Group study. J Pain Symptom Manage. 2010;39(5):839-846.
29. Schover LR. The impact of breast cancer on sexuality, body image, and intimate relationships. CA Cancer J Clin. 1991;41(2):112-120.
30. Ganz PA, Kwan L, Stanton AL, et al. Quality of life at the end of primary treatment of breast cancer: first results from the moving beyond cancer randomized trial. J Natl Cancer Inst. 2004;96(5):376-387.
31. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570-579.
32. Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA, et al. Reliability and validity of the functional assessment of cancer therapy-ovarian. J Clin Oncol. 2001;19(6):1809-1817.
33. Wenzel L, Huang HQ, Monk BJ, et al. Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2005;23(24): 5605-5612.
34. Cella D, Lai J, Garcia SF, et al. The patient reported outcomes measurement information system - Cancer (PROMIS-Ca): Cancer-specific application of a generic fatigue measure. J Clin Oncol. 2008 ASCO Ann Meet Proc (Post-Meet Ed). 2008;26(No 15S May 20 suppl):6537. Abstract.
35. PROMIS: Patient Reported Outcomes Measurement System. http:// www.nihpromis.org/default.aspx. Accessed October 5, 2010.
36. McLachlan SA, Allenby A, Matthews J, et al. Randomized trial of coordinated psychosocial interventions based on patient self-assessments versus standard care to improve the psychosocial functioning of patients with cancer. J Clin Oncol. 2001;19(21):4117-4125.
37. Detmar SB, Muller MJ, Schornagel JH, et al. Health-related quality of life assessments and patient-physician communication: a randomized controlled trial. JAMA. 2002;288(23):3027-3034.
38. Velikova G, Booth L, Smith AB, et al. Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol. 2004;22(4):714-724.
39. von Gruenigen VE, Huang HQ, Gil KM, et al. Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials. Cancer. 2009;115(20):4857-4864.
40. Buchanan DR, O'Mara AM, Kelaghan JW, et al. Challenges and recommendations for advancing the state-of-the-science of quality of life assessment in symptom management trials. Cancer. 2007;110(7):1621-1628.